Risk factors of dapagliflozin-associated diabetic ketosis/ketoacidosis in patients with type 2 diabetes mellitus: A matched case-control study
Authors' conclusion
Current drinking, long T2DM duration, STEMI, acute infection, insulin deficiency, and major operation are the risk factors associated with DK/DKA in T2DM patients. Furthermore, long T2DM duration and STEMI were associated with more severe DK/DKA situations.
Study context
- Population
- Hospitalized T2DM patients taking dapagliflozin, general hospital in China, 2018–20211,684 hospitalized on dapagliflozin
- Participants
- 137 vs 137
- Comparison
- Dapagliflozin-associated DK/DKA vs non-DK/DKA controls
- DK/DKAn = 137
- non-DK/DKAn = 137reference
- Outcome
- Risk factors of dapagliflozin-associated DK/DKA
Methodological detailssingle-centre, matched on baseline characteristics
- Single-centre
- Matched on baseline characteristics
Main finding
As reported in the abstract
Risk factors for dapagliflozin-associated DK/DKA (logistic regression)
- Current drinking: OR 7.656
- p < 0.001
- T2DM duration ≥ 7.625 years: OR 2.399
- p = 0.017
- Acute ST-elevations myocardial infarction (STEMI): OR 12.770
- p = 0.028
- Acute infection: OR 2.862
- p = 0.043
- Insulin dose reduction/cessation before dapagliflozin exposure: OR 6.751
- p < 0.001
- Major plus or major operation: OR 2.652
- p = 0.022
Observational data: associations, not effects.
Further findings
- Time-to-onset of DK/DKA
- 28.59 · mean · days
Incidence of dapagliflozin-associated DK/DKA
- Diagnosed with DK/DKA among 1,684 hospitalized patients taking dapagliflozin
- 170
Factors independently associated with more severe DK/DKA
- T2DM duration ≥ 7.625 years
- P = 0.046
- Acute STEMI
- P < 0.001
Original publication
Risk factors of dapagliflozin-associated diabetic ketosis/ketoacidosis in patients with type 2 diabetes mellitus: A matched case-control study. Diabetes Res Clin Pract. Published 5 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →